|
Disclosure Statement
According to the disclosure policy of the American Academy of CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any significant relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for fair balance, scientific objectivity of studies reported, and patient-care recommendations.
The existence of these interests or relationships is not viewed a implying bias or decreasing the value of the presentation.
Off-label Disclosure Statement
At the time of the release of this CME/CE activity, the following non-FDA-approved uses of antifungal agents are discussed in this online educational activity: Amphotericin B deoxycholate and lipid formulations of amphotericin B as prophylaxis for invasive fungal infections; itraconazole as prophylaxis for invasive fungal infections; voriconazole as prophylaxis and salvage therapy for invasive fungal infections; and posaconazole as empiric treatment for invasive fungal infections and febrile neutropenia, as well as salvage therapy for invasive fungal infections.
| 
